BACKGROUND: The estimation of the risk of poor tolerance and overdose of antineoplastic agents protocols represents a major challenge in oncology, particularly in older patients. We hypothesize that age-related modifications of body composition (i.e. increased fat mass and decreased lean mass) may significantly affect tolerance to chemotherapy. METHOD: We conducted a systematic review for the last 25 years (between 1990 and 2015), using US National library of Medicine Medline electronic bibliographic database and Embase database of cohorts or clinical trials exploring (i) the interactions of body composition (assessed by Dual X-ray Absorptiometry, Bioelectrical Impedance Analyses, or Computerized Tomography) with pharmacokinetics parameters, (ii) the tolerance to chemotherapy, and (iii) the consequences of chemotherapies or targeted therapies on body composition. RESULTS: Our search identified 1504 articles. After a selection (using pre-established criteria) on titles and abstract, 24 original articles were selected with 3 domains of interest: impact of body composition on pharmacokinetics (7 articles), relationship between body composition and chemotoxicity (14 articles), and effect of anti-cancer chemotherapy on body composition (11 articles). The selected studies suggested that pharmacokinetic was influenced by lean mass, that lower lean mass could be correlated with toxicity, and that sarcopenic patients experienced more toxicities that non-sarcopenic patients. Regarding fat mass, results were less conclusive. No studies specifically explored the topic of body composition in older cancer patients. CONCLUSIONS: Plausible pathophysiological pathways linking body composition, toxicity, and pharmacokinetics are sustained by the actual review. However, despite the growing number of older cancer patients, our review highlighted the lack of specific studies in the field of anti-neoplastic agents toxicity regarding body composition conducted in elderly.
BACKGROUND: The estimation of the risk of poor tolerance and overdose of antineoplastic agents protocols represents a major challenge in oncology, particularly in older patients. We hypothesize that age-related modifications of body composition (i.e. increased fat mass and decreased lean mass) may significantly affect tolerance to chemotherapy. METHOD: We conducted a systematic review for the last 25 years (between 1990 and 2015), using US National library of Medicine Medline electronic bibliographic database and Embase database of cohorts or clinical trials exploring (i) the interactions of body composition (assessed by Dual X-ray Absorptiometry, Bioelectrical Impedance Analyses, or Computerized Tomography) with pharmacokinetics parameters, (ii) the tolerance to chemotherapy, and (iii) the consequences of chemotherapies or targeted therapies on body composition. RESULTS: Our search identified 1504 articles. After a selection (using pre-established criteria) on titles and abstract, 24 original articles were selected with 3 domains of interest: impact of body composition on pharmacokinetics (7 articles), relationship between body composition and chemotoxicity (14 articles), and effect of anti-cancer chemotherapy on body composition (11 articles). The selected studies suggested that pharmacokinetic was influenced by lean mass, that lower lean mass could be correlated with toxicity, and that sarcopenic patients experienced more toxicities that non-sarcopenicpatients. Regarding fat mass, results were less conclusive. No studies specifically explored the topic of body composition in older cancerpatients. CONCLUSIONS: Plausible pathophysiological pathways linking body composition, toxicity, and pharmacokinetics are sustained by the actual review. However, despite the growing number of older cancerpatients, our review highlighted the lack of specific studies in the field of anti-neoplastic agents toxicity regarding body composition conducted in elderly.
Authors: Samantha J Cushen; Derek G Power; Min Y Teo; Peter MacEneaney; Michael M Maher; Ray McDermott; Kathleen O'Sullivan; Aoife M Ryan Journal: Am J Clin Oncol Date: 2017-02 Impact factor: 2.339
Authors: Massimo Breccia; Luca Mazzarella; Vincenzo Bagnardi; Davide Disalvatore; Giuseppina Loglisci; Giuseppe Cimino; Anna Maria Testi; Giuseppe Avvisati; Maria Concetta Petti; Clara Minotti; Roberto Latagliata; Robin Foà; Pier Giuseppe Pelicci; Francesco Lo-Coco Journal: Blood Date: 2011-11-02 Impact factor: 22.113
Authors: G Del Rio; S Zironi; L Valeriani; R Menozzi; M Bondi; M Bertolini; L Piccinini; M C Banzi; M Federico Journal: Breast Cancer Res Treat Date: 2002-06 Impact factor: 4.872
Authors: Theodore R McRackan; John M Watkins; Amy E Herrin; Elizabeth M Garrett-Mayer; Anand K Sharma; Terry A Day; M Boyd Gillespie Journal: Laryngoscope Date: 2008-07 Impact factor: 3.325
Authors: Carla M M Prado; Yara L M Maia; Michael Ormsbee; Michael B Sawyer; Vickie E Baracos Journal: Anticancer Agents Med Chem Date: 2013-10 Impact factor: 2.505
Authors: Sophie Cousin; A Hollebecque; S Koscielny; O Mir; A Varga; V E Baracos; J C Soria; S Antoun Journal: Invest New Drugs Date: 2013-12-17 Impact factor: 3.850
Authors: Connie Yip; Vicky Goh; Andrew Davies; James Gossage; Rosalind Mitchell-Hay; Orla Hynes; Nick Maisey; Paul Ross; Andrew Gaya; David B Landau; Gary J Cook; Nyree Griffin; Robert Mason Journal: Eur Radiol Date: 2014-02-18 Impact factor: 5.315
Authors: Hannah C Timmins; David Mizrahi; Tiffany Li; Matthew C Kiernan; David Goldstein; Susanna B Park Journal: J Cancer Surviv Date: 2021-01-12 Impact factor: 4.442
Authors: M-E Rougé Bugat; M Bourgouin; S Gérard; S Lozano; D Brechemier; P Cestac; C Cool; L Balardy Journal: J Nutr Health Aging Date: 2017 Impact factor: 4.075
Authors: Hannah C Timmins; Tiffany Li; David Goldstein; Terry Trinh; David Mizrahi; Michelle Harrison; Lisa G Horvath; Michael Friedlander; Matthew C Kiernan; Susanna B Park Journal: J Cancer Surviv Date: 2021-02-27 Impact factor: 4.442
Authors: Stéphanie M L M Looijaard; Miriam L Te Lintel Hekkert; Rob C I Wüst; René H J Otten; Carel G M Meskers; Andrea B Maier Journal: Acta Physiol (Oxf) Date: 2020-07-24 Impact factor: 6.311
Authors: Willemieke P M Dijksterhuis; Maarten J Pruijt; Stephanie O van der Woude; Remy Klaassen; Sophie A Kurk; Martijn G H van Oijen; Hanneke W M van Laarhoven Journal: J Cachexia Sarcopenia Muscle Date: 2019-01-21 Impact factor: 12.910